Fig. 8From: Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritisRadiographic damage as per patient-level mTSS and MDA over 52 weeks of secukinumab treatment. MDA, minimal disease activity; mTSS, modified total Sharp score; N, total number of patientsBack to article page